Observational studyHuman vaccines & immunotherapeutics2023

Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China.

Yuan-Yuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.